Spots Global Cancer Trial Database for primary tumor
Every month we try and update this database with for primary tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms | NCT05038358 | Primary Tumor Colon Tumor | 18 Years - | University Hospital, Grenoble | ||
To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors | NCT02410174 | Primary Tumor Renal Cell Carc... | Stereotactic Bo... | 18 Years - | Beth Israel Medical Center | |
ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
Comparison of Gene Mutations in Matched Samples in Advanced Nonsquamous NSCLC Using NGS | NCT02416726 | Lung Cancer | Nextseq500 sequ... | 18 Years - 80 Years | Shanghai Chest Hospital | |
ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
ARQ 197 in Subjects With Metastatic Solid Tumors | NCT00302172 | Cancer Tumor | ARQ 197 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases | NCT02301858 | Lung Cancer Primary Tumor Metastases | Genome analysis... | 18 Years - 90 Years | Sykehuset i Vestfold HF | |
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms | NCT05038358 | Primary Tumor Colon Tumor | 18 Years - | University Hospital, Grenoble |